logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10392422 B1

PDFFull Text
Date of Patent:
Aug. 27, 2019

Filed:

May. 19, 2015

Macrocyclic broad spectrum antibiotics

Applicants:

Rqx Pharmaceuticals, Inc., La Jolla, CA (US);

Genentech, Inc., San Francisco, CA (US);

Inventors:

Tucker Curran Roberts, San Diego, CA (US);

Peter Andrew Smith, San Francisco, CA (US);

Robert I. Higuchi, Solana Beach, CA (US);

Prasuna Paraselli, San Diego, CA (US);

Philippe Bergeron, Redwood City, CA (US);

Michael F. T. Koehler, Palo Alto, CA (US);

Huiyong Hu, Fremont, CA (US);

Jacob Bradley Schwarz, San Ramon, CA (US);

Cuong Ly, Burlingame, CA (US);

James John Crawford, San Francisco, CA (US);

Assignees:

RQX PHARMACEUTICALS, INC., La Jolla, CA (US);

GENENTECH, INC., South San Francisco, CA (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Thomas S Heard

Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 5/103 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 5/02 (2006.01); C07K 5/087 (2006.01); C07K 5/09 (2006.01); C07K 5/11 (2006.01); A61K 45/06 (2006.01); A61K 31/395 (2006.01); A61K 31/407 (2006.01); A61K 31/4196 (2006.01); A61K 31/43 (2006.01); A61K 31/431 (2006.01); A61K 31/496 (2006.01); A61K 31/545 (2006.01); A61K 31/546 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 38/08 (2019.01); C07K 5/083 (2006.01); A61K 38/12 (2006.01);
U.S. Cl.
CPC ...
C07K 5/101 (2013.01); A61K 31/395 (2013.01); A61K 31/407 (2013.01); A61K 31/4196 (2013.01); A61K 31/43 (2013.01); A61K 31/431 (2013.01); A61K 31/496 (2013.01); A61K 31/545 (2013.01); A61K 31/546 (2013.01); A61K 38/06 (2013.01); A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 45/06 (2013.01); C07K 5/0202 (2013.01); C07K 5/0808 (2013.01); C07K 5/0812 (2013.01); C07K 5/0815 (2013.01); C07K 5/1008 (2013.01); C07K 5/1013 (2013.01); C07K 5/1019 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); A61K 38/00 (2013.01); A61K 38/12 (2013.01); Y02A 50/401 (2018.01); Y02A 50/47 (2018.01); Y02A 50/471 (2018.01); Y02A 50/473 (2018.01); Y02A 50/475 (2018.01); Y02A 50/478 (2018.01); Y02A 50/483 (2018.01);
Abstract

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Find Patent Forward Citations

Loading…